{
    "id": 15723,
    "cites": 24,
    "cited_by": 1,
    "reference": [
        "Aitken, M., Berndt, E.R., Cutler, D.M. (2009) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Prescription Drug Spending Trends in the United States: Looking Beyond the Turning Point.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Health Affairs, 28(1).",
        "Cook, A. (1998) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093How Increase Competition from Generic Drugs Has Affected Prices and Returns in the Pharmaceutical Industry.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Congressional Budget Office Study.",
        "DiMasi, J.A., Hansen, R.W. and Grabowski, H.G. (2003) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Price of Innovation: New Estimates of Drug Development Costs.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Health Economics 22: 151\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c85.",
        "DiMasi, J.A. (2003) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Capitalized Cost per Approved Drug\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Tufts Center for the Study of Drug Development. Massachusetts Institute of Technology presentation on biotechnology strategy. Available at: web.mit.edu/biostrategy/files/031204_DiMasi_Slides.ppt.",
        "Giaccotto, C., Santerre, R. and Vernon, J.A. (2005) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Drug Prices and Research and Development Investment Behavior in the Pharmaceutical Industry.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Law and Economics 48: 195\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c 214.",
        "Golec, J., Hegde, S., and Vernon, J.A. (2010) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Pharmaceutical R&D Spending and Price Constraint Threats.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Forthcoming in Journal of Financial and Quantitative Analysis.",
        "Grabowski, H.G. (1968) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Determinants of Industrial Research and Development: A Study of the Chemical, Drug, and Petroleum Industries.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Political Economy 76: p. 292.",
        "Grabowski, H. G. and Vernon J. M. (1981) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Determinants of R&D Expenditures in the Pharmaceutical Industry,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d in Drugs and Health: Economic Issues and Policy Objectives 3 (ed. Robert B. Helms).",
        "Grabowski, H.G. and Vernon, J.M. (1992) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Brand Loyalty, Entry and Price Competition in Pharmaceuticals after the 1984 Act.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d The Journal of Law and Economics 35: 331.",
        "Grabowski, H.G. (1994) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Health Reform and Pharmaceutical Innovation.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d AEI Press.",
        "Washington, D.C. Grabowski, H. G. and Vernon J. M. (2000) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Determinants of Pharmaceutical Research and Development Expenditures.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Evolutionary Economics, 10: 201-215.",
        "Grabowski, H.G. (2003) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Patents and New Product Development in the Pharmaceuticals and Biotechnology Industries.\" Edited by John Duca, Federal Reserve Bank of Dallas, 87-104.",
        "Hall, B. (1992). \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Investment and Research and Development at the Firm Level: Does the Source of Financing Matter?\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d National Bureau of Economic Research, working paper 4096, Cambridge, MA.",
        "Hubbard, G. (1998) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Capital Market Imperfections and Investment,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Economic Literature, vol. XXXVI.",
        "Lichtenberg, F.R. (2002). \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Sources of U.S. Longevity Increase, 1960-1997.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d National Bureau of Economic Research, working paper 8755, Cambridge, MA.",
        "Malmendier and Tate (2005) . \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093.CEO Overconfidence and Corporate Investment\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, Journal of Finance, December 2005, vol. 60 (6), pp. 2661-2700.",
        "Murphy, Kevin M., and Robert H. Topel. 2003a. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The economic value of medical research.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d In Measuring the Gains from Medical Research: An Economic Approach, ed. Kevin M. Murphy and Robert H. Topel, 41\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c73. Chicago: University of Chicago Press.",
        "Reiffen, D and M. Ward (2005) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Generic Drug Industry Dynamics,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Review of Economics and Statistics, 87, 37-49.",
        "Scherer, F.M. (1996) Industry Structure, Strategy, and Public Policy. Harper Collins.",
        "Scherer, F.M. (2001) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Link Between Gross Profitability And Pharmaceutical R&D Spending,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Health Affairs 20(5): 216-220.",
        "U.S. Federal Trade Commission (2009) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Authorized Generics: An Interim Report\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d. Federal Trade Commission Report.",
        "Vernon, J.A. (2005). \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Examining the Link between Price Regulation and Pharmaceutical R&D Investment.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Health Economics (14):1, 1-17.",
        "Vernon, J.A., Golec, J., Lutter, R., and Nardinelli, C. (2009) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093An Exploratory Study of FDA New Drug Approval Times, Prescription Drug User Fees, and R&D Spending.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d The Quarterly Review of Economics and Finance 49(4):1260-1275.",
        "Vernon, J.A., Golec, J., and DiMasi, J. (2010) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Drug Development Costs when Financial Risk is Measured Using the Fama-French Three-factor Model.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Forthcoming in Health Economics."
    ]
}